SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Hjortland G. O.)
 

Sökning: WFRF:(Hjortland G. O.) > Oncological outcome...

  • Nilsson, K.Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm; Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm,Karolinska Univ Hosp, Sweden; Karolinska Inst, Sweden (författare)

Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • Elsevier,2023
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:umu-215232
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-215232URI
  • https://doi.org/10.1016/j.annonc.2023.08.010DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-200052URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:154441570URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies|Stockholm Medical Research Funds [20200119]
  • Background: The optimal time to surgery (TTS) after neoadjuvant chemoradiotherapy (nCRT) for oesophageal cancer is unknown and has traditionally been 4-6 weeks in clinical practice. Observational studies have suggested better outcomes, especially in terms of histological response, after prolonged delay of up to 3 months after nCRT. The NeoRes II trial is the first randomised trial to compare standard to prolonged TTS after nCRT for oesophageal cancer.Patients and methods: Patients with resectable, locally advanced oesophageal cancer were randomly assigned to standard delay of surgery of 4-6 weeks or prolonged delay of 10-12 weeks after nCRT. The primary endpoint was complete histological response of the primary tumour in patients with adenocarcinoma (AC). Secondary endpoints included histological tumour response, resection margins, overall and progression-free survival in all patients and stratified by histologic type.Results: Between February 2015 and March 2019, 249 patients from 10 participating centres in Sweden, Norway and Germany were randomised: 125 to standard and 124 to prolonged TTS. There was no significant difference in complete histological response between AC patients allocated to standard (21%) compared to prolonged (26%) TTS (P = 0.429). Tumour regression, resection margins and number of resected lymph nodes, total and metastatic, did not differ between the allocated interventions. The first quartile overall survival in patients allocated to standard TTS was 26.5 months compared to 14.2 months after prolonged TTS (P = 0.003) and the overall risk of death during follow-up was 35% higher after prolonged delay (hazard ratio 1.35, 95% confidence interval 0.94-1.95, P = 0.107).Conclusion: Prolonged TTS did not improve histological complete response or other pathological endpoints, while there was a strong trend towards worse survival, suggesting caution in routinely delaying surgery for >6 weeks after nCRT.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Klevebro, F.Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm; Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm,Karolinska Univ Hosp, Sweden; Karolinska Inst, Sweden (författare)
  • Sunde, B.Karolinska Institutet (författare)
  • Rouvelas, I.Karolinska Institutet (författare)
  • Lindblad, M.Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm; Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm,Karolinska Univ Hosp, Sweden; Karolinska Inst, Sweden (författare)
  • Szabo, E.Department of Surgery, Faculty of Medicine and Health, Örebro University Hospital, Örebro,Orebro Univ Hosp, Sweden (författare)
  • Halldestam, IngvarUniversity Hospital of Linköping, Linköping,Region Östergötland, Kirurgiska kliniken US(Swepub:liu)ingha61 (författare)
  • Smedh, U.Department of Surgery, Sahlgrenska University Hospital, Gothenburg,Sahlgrens Univ Hosp, Sweden (författare)
  • Wallner, Bengt,1962-Umeå universitet,Kirurgi,Umea Univ, Sweden(Swepub:umu)bewa0005 (författare)
  • Johansson, J.Department of Surgery, Skåne University Hospital, Lund, Sweden,Skane Univ Hosp, Sweden,Oslo Univ Hosp, Norway (författare)
  • Johnsen, G.Department of Gastrointestinal Surgery, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway,Univ Trondheim Hosp, Norway (författare)
  • Aahlin, E.K.Department of GI and HPB Surgery, University Hospital of Northern Norway, Tromsø,Univ Hosp Northern Norway, Norway (författare)
  • Johannessen, H.-O.Department of Gastrointestinal Surgery, Oslo University Hospital, Oslo, Norway (författare)
  • Alexandersson von Döbeln, G.Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm; Medical Unit of Head, Neck, Lung and Skin Cancer, Karolinska University Hospital, Stockholm, Sweden,Karolinska Univ Hosp, Sweden; Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden (författare)
  • Hjortland, G.O.Department of Oncology, Oslo University Hospital, Oslo, Norway,Oslo Univ Hosp, Norway (författare)
  • Wang, N.Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm,Karolinska Univ Hosp, Sweden (författare)
  • Shang, Y.Karolinska Institutet (författare)
  • Borg, D.Department of Oncology, Skåne University Hospital, Lund, Sweden,Skane Univ Hosp, Sweden (författare)
  • Quaas, A.Institute of Pathology, University of Cologne, Cologne,Univ Cologne, Germany (författare)
  • Bartella, I.Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital of Cologne, Cologne, Germany,Univ Hosp Cologne, Germany (författare)
  • Bruns, C.Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital of Cologne, Cologne, Germany,Univ Hosp Cologne, Germany (författare)
  • Schröder, W.Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital of Cologne, Cologne, Germany,Univ Hosp Cologne, Germany (författare)
  • Nilsson, M.Karolinska Institutet (författare)
  • Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm; Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, StockholmKarolinska Univ Hosp, Sweden; Karolinska Inst, Sweden (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Annals of Oncology: Elsevier34:11, s. 1015-10240923-75341569-8041

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy